Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway.Members of the type I and type II cytokine receptor families depend on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways because they lack catalytic kinase activity.The receptors have two intracellular signal-transducing domains because they are paired polypeptides. Each intracellular domain contains a proline-rich region called a box1/box2 region that is close to the cell membrane and where JAKs bind. The two JAKs are brought close enough to phosphorylate one another after the receptor undergoes a conformational change following association with the corresponding cytokine or ligand. By further phosphorylating and activating STAT transcription factors, JAK autophosphorylation causes a conformational change within itself, enabling it to transduce the intracellular signal. When STATs are activated, they separate from their receptor and coalesce into dimers before moving into the cell nucleus, where they control the transcription of particular genes.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V55046 | LRRK2-IN-8 | 2770269-44-6 | LRRK2-IN-8 is an LRRK2 inhibitor. |
|
V55047 | LRRK2/NUAK1/TYK2-IN-1 | 2629192-96-5 | LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory effect against LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1 with IC50 less than 10 nM. |
|
V85823 | MMT3-72 | 2996158-39-3 | |
|
V85953 | MMT3-72-M2 | 936091-74-6 | |
|
V34785 | Niclosamide olamine (BAY2353 olamine) | 1420-04-8 | Niclosamide (BAY2353) olamine is an orally bioactive antihelmintic compound utilized in the research of parasitic infections. |
|
V56215 | Niclosamide-13C6 monohydrate (BAY2353-13C6 monohydrate) | 1325559-12-3 | Niclosamide-13C6 (monohydrate) is an orally bioactive antihelmintic compound utilized in the research of parasitic infections. |
|
V56221 | Nifuroxazide-d4 (nifuroxazide d4) | 1188487-83-3 | Nifuroxazide-d4 is the deuterium labelled form of Nifuroxazide. |
|
V51517 | Nimucitinib | 2740557-24-6 | Nimucitinib is a Janus kinase (JAK) inhibitor |
|
V41092 | NSC-370284 | 116409-29-1 | NSC-370284 is a selective inhibitor of 10-11 translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). |
|
V32016 | NVP-BSK805 | NVP-BSK805 is a novel, potent and selective ATP-competitive JAK2 inhibitor withIC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively. | |
|
V69736 | NVP-BSK805 | 1092499-93-8 | NVP-BSK805 is an ATP-competitive JAK2 inhibitor (antagonist) with IC50s of 0.48 nM, 31.63 nM, 18.68 nM and 10.76 nM for JAK2 JH1 (JAK homolog 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively. |
|
V0336 | NVP-BSK805 2HCl (BSK-805) | 1942919-79-0 | NVP-BSK805 2HCl (BSK805), the dihydrochloride salt of NVP-BSK805, is a novel, potent, selective and ATP-competitive JAK2 (Janus kinase) inhibitor with potential antitumor activity. |
|
V51507 | NVP-BSK805 trihydrochloride | 2320258-95-3 | NVP-BSK805 triHClide is an ATP-competitive JAK2 ligand with IC50s of 0.48 nM, 31.63 nM, 18.68 nM and 10.76 nM for JAK2 JH1 (JAK homolog 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively. |
|
V86138 | Pacritinib citrate (SB1518 citrate) | 1228923-42-9 | |
|
V3802 | PF-06700841 tosylate | 2140301-96-6 | Brepocitinib (PF-06700841) tosylate, the tosylate salt ofBrepocitinib,isa conformationally constrained piperazinyl-pyrimidine-based, Type 1 ATP site inhibitor of TYK2 and JAK1 kinases with IC50 values of 23 nM and 17 nM respectively. |
|
V104223 | PF-1367550 | 319461-60-4 | PF-1367550 is a pan-JAK inhibitor that reduces the levels of CXCL9, CXCL10, and CXCL11 released from primary airway epithelial cells. |
|
V88890 | pJAK2(1001–1013) | 1259928-08-9 | pJAK2(1001–1013) is a SOCS1/3 antagonist that enhances the JAK/STAT signaling pathway by inhibiting the negative regulatory effects of SOCS proteins, thereby playing a positive role in the antiviral immune response. |
|
V69738 | QL-1200186 | 2848664-42-4 | QL-1200186 is an orally bioactive and selective TYK2 inhibitor. |
|
V38108 | RSV A405 | 140405-36-3 | RSVA405 is a potent and orally bioactive AMPK activator with EC50 of 1 μM. |
|
V3369 | SAR-20347 | 1450881-55-6 | SAR-20347 is a novel and potent small molecule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2) over other JAK family members. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
